December 8, 2017 10:00 AM ESTUpdated 10:20 AM

Erytech shares crater as PhIIb AML study flops; Synlogic, Gingko collaborate on discovery work; Active Biotech forced to sell property due to Teva's drug failure

John Carroll

Editor & Founder

→ The French biotech Erytech Pharma $ERYP says that its Phase IIb trial of eryaspase for acute myeloid leukemia failed, triggering a rout of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Erytech shares crater as PhIIb AML study flops; Synlogic, Gingko collaborate on discovery work; Active Biotech forced to sell property due to Teva's drug failure

John Carroll

Editor & Founder

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Omada Health is going public on Friday at a $1.1B valuation

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

FDA's Makary looks at ways to speed drug approvals, talks about cutting user fees

Trump's health appointees pledge support for cell and gene therapies at FDA roundtable

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Ery­tech shares crater as PhI­Ib AML study flops; Syn­log­ic, Gingko col­lab­o­rate on dis­cov­ery work; Ac­tive Biotech forced to sell prop­er­ty due to Teva's drug fail­ure

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Erytech shares crater as PhIIb AML study flops; Synlogic, Gingko collaborate on discovery work; Active Biotech forced to sell property due to Teva's drug failure